Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04745910
PHASE4

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Sponsor: M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney function. The goal of this trial is to learn if pegloticase may lower uric acid levels in blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.

Official title: Effect of Pegloticase on Reduction of Uric Acid in Patients With Tumor Lysis Syndrome: A Pilot Pragmatic Clinical Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2022-04-05

Completion Date

2026-07-31

Last Updated

2025-12-18

Healthy Volunteers

No

Interventions

DRUG

Pegloticase

Given IV

DRUG

Rasburicase

Given IV

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States